Wednesday, December 15, 2010

Health Management (NYSE:HMA) Revenue Growth, EBITDA Progressing

Health Management (NYSE:HMA) revenue growth and EBITDA continue to progress nicely, and Barclays (NYSE:BCS) raised their price on the acute care hospital chain.

Barclays said, "HMA has shown continued signs of progress with better-than-expected revenue growth and EBITDA. Overall revenues have been better than expected, due to higher-than-expected revenue per adjusted admission growth. With the revenue upside, EBITDA has been stronger than anticipated."

Barclays maintains an "Overweight" on Health Management, which closed Tuesday at $9.29, up $0.17, or 1.86 percent. They raised their price target on them from $10 to $11.

1 comment:

Anonymous said...

Il semble que vous soyez un expert dans ce domaine, vos remarques sont tres interessantes, merci.

- Daniel